Parkinson's disease drug pipeline
- ICD-11 8A00.0
- MeSH D010300
Subtypes: Levodopa-induced dyskinesia in Parkinson's disease, Parkinson's disease psychosis
7 compounds from 7 companies are in active clinical development for parkinson's disease, including 3 at Phase 3 or beyond.
Mechanisms: Small molecule (7)
Pipeline data compiled September 2026 · every fact sourced.
Upcoming readouts & recent results
Phase 2 ITI-214-202 topline in Parkinson's disease (lenrispodun 30 mg vs placebo, Hauser-diary primary at Day 29). ↗
FDA decision on tavapadon NDA slipped past 1H 2026; trackers now expect September 2026 ↗
Anticipated Phase 2/3 topline in early Parkinson's disease (primary endpoint: time to first qualifying worsening on MDS-UPDRS Part II) ↗
AbbVie submitted the tavapadon NDA to the U.S. FDA for early and advanced Parkinson's disease. ↗
TEMPO-2 (flexible-dose monotherapy, early PD) met primary endpoint: -9.1 point treatment difference on MDS-UPDRS II+III (p<0.0001). ↗
TEMPO-1 (fixed-dose monotherapy, early PD) met primary endpoint at both 5 mg and 15 mg (p<0.0001 vs placebo). ↗
TEMPO-3 (adjunctive to levodopa, advanced PD) met primary endpoint: +1.1 h additional ON time without troublesome dyskinesia vs placebo (p<0.0001). ↗
Compounds in development (7)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| Rotigotine extended-release microspheres (LY03003)NMPA Priority Review (China; NDA Accepted 2023-08-01) | Luye Pharma Group Ltd. | Approved | Approved | D3 Agonist |
| ND0612 (levodopa/carbidopa continuous subcutaneous infusion) | Mitsubishi Tanabe Pharma Corporation | Filed (NDA) | Active | AADC Inhibitor |
| Tavapadon | AbbVie Inc. | Filed (NDA) | Active | D1 receptor Partial agonist |
| BHV-8000 | Biohaven Ltd. | Phase 2/3 | Recruiting | TYK2 Inhibitor |
| Lenrispodun (ITI-214) | Johnson & Johnson | Phase 2 | Active | PDE1B Inhibitor |
| Dalzanemdor | Sage Therapeutics, Inc. | Discontinued | Discontinued | NMDA receptor PAM |
| Sipagladenant | Kyowa Kirin Co., Ltd. | Discontinued | Discontinued | Adenosine A2A receptor Inverse agonist |
Trials recruiting now (123)
123 drug-interventional parkinson's disease trials recruiting now, of 1,331 registered interventional trials. Browse all on ClinicalTrials.gov →
Lemborexant, placebo
mirabegron
Overactive bladder antimuscarinic deprescribing
- Phase 4Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
Galantamine HBr extended-release 8mg capsules (8mg ER).
CREXONT ER
CREXONT ER
Vortioxetine (tablet)
MED ON plus
Carbidopa 25/Levodopa 100Mg Tab
Pimavanserin
Pimavanserin, Quetiapine
PD-RBD, iRBD
Showing the 12 most advanced of 123 recruiting drug trials · see all on ClinicalTrials.gov →
Frequently asked
- How many drugs are in development for parkinson's disease?
- 7 compounds from 7 companies are in active clinical development for parkinson's disease, including 3 at Phase 3 or beyond.
- Which parkinson's disease drugs are in Phase 3?
- Phase 3 (or later) programs for parkinson's disease include Rotigotine extended-release microspheres (LY03003), ND0612 (levodopa/carbidopa continuous subcutaneous infusion) and Tavapadon.
- What are the next parkinson's disease trial readouts?
- Upcoming catalysts include Lenrispodun (ITI-214) (2025), Tavapadon (Sep 2026 (third-party estimate)) and BHV-8000 (2H 2027).
- How many clinical trials are recruiting for parkinson's disease?
- 123 drug-interventional parkinson's disease trials are currently recruiting participants, out of 1,331 registered interventional trials.